Best Immunology Companies in New York City, United States
The 36 best Immunology companies in New York City, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Immunovant.
Ranked: Best Immunology companies in New York City
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunovant Provider of therapeutics solutions for treating autoimmune diseases 29Funding top 16%News top 45%Moat top 48%Tech bottom 48% All 7 signals ▾Fundingtop 16% Newstop 45% Moattop 48% Techbottom 48% Growthbottom 47% Globalbottom 41% Marketbottom 25% Funding: Raised $685M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) News: 7 BI events in 12 mo (of 46 tracked, 7 types) · -50% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $685M | 20 mo ago | 1 | 2016 | — | — | — |
| 2 | Everest Medicines Developer of drugs for the treatment of cancer | $593M | 75 mo ago | 395 | 2017 | Kerry Blanchard CEO | — | — |
| 3 | Immunic Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases 35Funding top 19%Tech top 41%Moat top 48%Growth top 50% All 9 signals ▾Fundingtop 19% Techtop 41% Moattop 48% Growthtop 50% Talentbottom 49% Globalbottom 45% Newsbottom 40% Marketbottom 38% Fin. healthbottom 20% Funding: Raised $560M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) Tech: 34 technologies across 3/8 capability areas · Cloud: Cloudflare, Google Cloud rank vs industry peers · Fliar Intelligence Index 35/100 | $560M | 7 mo ago | 77 77 → 91 (+18%) | 2003 | Daniel Vitt Chief Executive Officer | — | — |
| 4 | Flame Biosciences Manufacturer of drugs for treating inflammation | $109M | 71 mo ago | — | 2019 | Charles Fisher Founder | — | — |
| 5 | Graviton Bioscience Developer of novel therapeutics for the treatment of autoimmune, cancer, and other serious diseases | $65M | 31 mo ago | — | 2020 | Samuel Waksal Founder & CEO | — | — |
| 6 | Olatec Biopharmaceutical company developing NLRP3 antagonist therapeutics for inflammatory diseases | $40M | 42 mo ago | 8 | 2003 | — | — | — |
| 7 | RenBio Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases | $29M | 24 mo ago | 10 10 → 8 (-20%) | 2016 | David Ho Co-Founder | 11 patents Nucleic acid delivery devices and plasmid expression vectors for therapeutic proteins | — |
| 8 | Graviton Bioscience Biotech company focused on developing therapies to cure diseases through restored homeostasis | $25M | 32 mo ago | — | 2023 | Samuel Waksal Chief Executive Officer | — | — |
| 9 | Kadmon Vertically integrated biopharmaceutical company targeting Autoimmune and Fibrotic Diseases, Oncology… | $21M | 107 mo ago | 127 | 2009 | — | 289 patents Small-molecule kinase inhibitor therapies and solid drug formulations for chronic GVHD | — |
| 10 | Ceramedix Developer of therapies for multiple immune-related diseases | $12M | 20 mo ago | 4 | 2020 | Charles Dimmler CEO | — | — |
| 11 | NILO Therapeutics Developer of therapeutics for immunological disorders | $10M | 26 mo ago | — | — | — | — | — |
| 12 | Tonix Pharma Developer of next-generation medicines for CNS and immunological disorders | $4M | 17 mo ago | 117 117 → 169 (+44%) | 2007 | — | — | — |
| 13 | Ancilia Developer of microbiome therapies for immunology and oncology indications 19Funding top 37%Patents top 41%Innovation bottom 49%Moat bottom 49% All 7 signals ▾Fundingtop 37% Patentstop 41% Innovationbottom 49% Moatbottom 49% Globalbottom 43% Marketbottom 20% Newsbottom 18% Funding: Raised $4.2M across 6 rounds · 6 rounds over 2 yrs (3.0/yr) Patents: 11 patents matched (strict assignee match) · 9 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 19/100 | $4M | 7 mo ago | 5 | 2019 | — | 11 patents Blockchain security detection/profiling and microbiome modulation therapeutic compositions | — |
| 14 | Nionyx Bio Developer of gene therapy solutions designed for precision and safety | $4M | 11 mo ago | — | 2025 | Leszek Lisowski Co-Founder | — | — |
| 15 | Araim Pharmaceuticals E-commerce platform offering diverse products, from electronics to fashion and groceries | $4M | 106 mo ago | 3 | 2006 | Michael Brines Co-Founder | 123 patents Peptide therapeutics for tissue protection and regeneration in injury-related diseases | — |
| 16 | Immune Pharmaceuticals Developer of therapeutic agents for the treatment of immunologic and inflammatory diseases | $4M | 106 mo ago | 9 | 1993 | — | — | — |
| 17 | Intrommune Developing oral mucosal immunotherapy toothpaste for food allergy management | $3M | 33 mo ago | 15 | 2015 | Michael Nelson Founder & CEO | — | — |
| 18 | Akari Therapeutics Developer of therapeutics for autoimmune and inflammatory diseases by targeting the complement system. | $2M | 9 mo ago | 5 | 2005 | Ray Prudo Chairman | — | — |
| 19 | Mercia Pharma Vaccine in combination with adjuvants for autoimmune, CNS, respiratory and infectious diseases | $2M | 206 mo ago | — | 2004 | Peter Blackburn President and Founder | — | — |
Top 12 Immunology companies in New York City
#1
Public · New York City, New York · founded 2003 · 77 employees$559.7Mraised▾
Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases. The product pipeline of the company includes vidofludimus calcium (IMU-838), a selective immune modulator for multiple sclerosis, IMU-935, a selective inverse agonist targeted for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome and IMU-856, for bowel barrier dysfunction.
- Feb 2026Post IPO$400M
- Jan 2024Post IPO$80M
- Oct 2022Post IPO$60M
- Sep 2016Post IPO$19.7M
#2
Public · New York City, New York · founded 2016 · 1 employees$685Mraised▾
Provider of therapeutic solutions to treating autoimmune diseases. The company's product line include, IMVT-1401, is a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient needs and a range of autoimmune diseases. The candidate is meant for diseases like Myasthenia Gravis, and Graves’ Ophthalmopathy.
- Jan 2025Post IPO$450M
- Jan 2022Post IPO—
- Aug 2021Post IPO$200M
- Oct 2019Conventional Debt$35M
#3
Series B · New York City, New York · founded 2019 · 5 employees$4.2Mraised▾
Developer of microbiome therapies for immunology and oncology indications. It offers bacterial therapeutics that target the viral components of the microbiome to treat chronic diseases. The therapies are based on CRISPR technology that enhances bacterial immunity against viruses and modulates the human microbiome.
- Feb 2026Series B$10.1M
- Aug 2025Grant (prize money)$274.4K
- Jul 2025Grant (prize money)$274.4K
- Sep 2024Grant (prize money)$274.4K
#4
Public · New York City, New York · founded 2005 · 5 employees$2.4Mraised▾
Developer of therapeutics for autoimmune and inflammatory diseases by targeting the complement system. Its lead candidate is Nomacopan is being evaluated for four therapeutic areas which include bullous pemphigoid (BP), a severe blistering skin disease, thrombotic microangiopathy, AMD, and asthma. It is also developed compounds that inhibit the leukotriene system such as thromboxane A2.
- Dec 2025Post IPO—
- Mar 2025Post IPO$7.6M
- Dec 2023Post IPO—
- Jul 2021Post IPO$12.3M
#5
Seed · New York City, New York · founded 2025$4Mraised▾
Developer of gene therapy solutions designed for precision and safety. The company focuses on capsid, cassette, and delivery methods. It engineers solutions for specific applications. The company aims to advance the future of gene therapy.
- Sep 2025Seed$4M
#6
Public · New York City, New York · founded 2007 · 117 employees$4.5Mraised▾
Developer of next-generation medicines for CNS and immunological disorders. The lead product of the company is TNX-601 (tianeptine oxalate), for the treatment of Post-traumatic stress disorder (PTSD), and TNX-801 for horsepox virus.
- Apr 2025Grant (prize money)$5.2M
- Feb 2025Grant (prize money)$5.2M
- Oct 2022Post IPO$15M
- Aug 2022Grant (prize money)—
#7
Funding Raised · New York City, New York · founded 2020 · 4 employees$11.9Mraised▾
Developer of therapies for multiple immune-related diseases. It offers therapies for endothelial tissue protection and repair for treating multiple disease that affect the vascular endothelium of the eye, lung, kidney, and other organs.
- Jan 2025Grant (prize money)$6M
- Jun 2020Grant (prize money)$6M
#8
Series A · New York City, New York · founded 2016 · 10 employees$29.2Mraised▾
Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases. The company's proprietary MYO technology involves in the development of antibody therapeutic that helps in treating rare diseases, viral infections, autoimmune diseases, and more by using DNA blueprint & antibody factory.
- Aug 2024Series A$5.2M
- Jan 2021Series A$24M
- Jul 2016Grant (prize money)$3.4M
#9
Series C · New York City, New York · founded 2020$64.8Mraised▾
Developer of novel therapeutics for the treatment of autoimmune, cancer, and other serious diseases. It offers a lead candidate TDI01 a potent inhibitor of Rho/Rho associated coiled-coil containing protein kinase 2 (ROCK2) for the treatment of idiopathic pulmonary fibrosis.
- Feb 2024Series C—
- Nov 2023Series C$25M
- Dec 2022Series C$39.8M
#10
Public · New York City, New York · founded 2017 · 395 employees$593Mraised▾
Developer of drugs for the treatment of cancer. The company has a portfolio of eight promising drug candidates for oncology, immunology, cardio-renal disease, and infectious disease. The company is developing kinase inhibitors that include FGF401 which is a fibroblast growth factor receptor 4 kinase inhibitor used to treat cancer.
- Jun 2020Series C$260M
- Mar 2020Series C$50M
- 2018Series A$3M
#11
Series A · New York City, New York$9.6Mraised▾
Developer of therapeutics for immunological disorders
#12
Series B · New York City, New York · founded 2023$25Mraised▾
Biotech company focused on developing therapies to cure diseases through restored homeostasis. The company focuses on the clinical development of GV101 and its pipeline of ROCK2 inhibitors to treat a range of serious fibrotic, inflammatory and neurologic conditions.
- Jan 2024Series B$25M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in the United States
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,913 United States-affiliated papers.
- Dana-Farber Cancer Institute608
- The University of Texas MD Anderson Cancer Center559
- Harvard University524
- Cornell University416
- Brigham and Women's Hospital408
- Immune system88→1414
- Tumor microenvironment30→481
- Cancer41→483
- Cancer immunotherapy35→460
- T cell23→340
- Immune system205→2094
- Cancer86→884
- Oncology71→760
- Internal medicine109→672
- Tumor microenvironment72→632
- Immune system67→663
- Cancer40→389
- Oncology24→257
- Disease16→242
- Clinical trial11→209
Where immunology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing immunology patents in the United States
United States immunology patent filing is accelerating — 10,389 filings from 4,528 assignees (2016–2025), led by UNIV California, Memorial Sloan Kettering Cancer , US Health; annual filings 785→970.
- UNIV California399
- Memorial Sloan Kettering Cancer 350
- US Health315
- UNIV Texas296
- Iovance Biotherapeutics284
- Abbvie270
- UNIV Pennsylvania237
- DANA Farber Cancer INST222
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.